Citations

Clear

382 citation(s) found for "Whitwell, Jennifer L".

Utilizing quantitative susceptibility mapping to differentiate primary lateral sclerosis from progressive supranuclear palsy: A case report
Sekiya, Hiroaki , Satoh, Ryota , Ali, Farwa , Whitwell, Jennifer L., Josephs, Keith A. , Josephs, Keith A , Sekiya, Hiroaki , Satoh, Ryota , Dickson, Dennis W. , Whitwell, Jennifer

Mayo Clinic

Neuropathology | November 19, 2024 | Volume: 45 | Issue: 3 | Pages: 223-227

10.1111/neup.13015 | PMID 39557402 Get It

We report a patient who presented clinically with progressive supranuclear palsy (PSP) but was pathologically diagnosed as having primary lateral sclerosis (PLS) with magnetic resonance imaging (MRI) with a quantitative susceptibility mapping (QSM) protocol. A 70‐year‐old man was clinically diagnosed with PSP due to early falls and unresponsiveness to levodopa therapy. Postmortem pathological examination revealed mild loss of Betz cells, gliosis, and transactive response DNA binding protein of 43 kDa (TDP‐43)‐positive inclusions in the motor cortex, leading to the pathological diagnosis of PLS. To explore methods for differentiating PLS from PSP, ante‐mortem QSM images were visually and quantitatively assessed for abnormal increases in magnetic susceptibility in the motor cortex. Prussian blue and Luxol fast blue combined with periodic acid‐Schiff staining were also performed to understand the source of the susceptibility increases. QSM showed clear hyperintense signals in the motor cortex. Magnetic susceptibility in the motor cortex was higher in the PLS patient (Z = 4.7, p < 0.001) compared to normal controls and pathologically diagnosed PSP patients. Pathological examination of the region showed intracortical myelin loss, as well as iron deposition. Underlying pathological processes for the increased magnetic susceptibility include not only iron deposition but also intracortical myelin. Our case suggests that QSM is a potential tool to differentiate PLS from PSP, providing insights for accurate diagnosis and enhancing clinical decision‐making.
Progression of Motor Speech Function in Speakers With Primary Progressive Apraxia of Speech
Meade, Gabriela , Pham, Nha Trang Thu, Clark, Heather M. , Duffy, Joseph R. , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L. , Thu Pham, Nha Trang , Meade, Gabriela , Utianski, Rene L , Clark, Heather M , Duffy, Joseph R , Whitwell, Jennifer L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | November 15, 2024 | Volume: 67 | Issue: 12 | Pages: 4651-4662

10.1044/2024_jslhr-24-00283 | PMID 39546410 Get It

Purpose: Speakers with primary progressive apraxia of speech (PPAOS) have an insidious onset of motor speech planning/programming difficulties. As the disease progresses, the apraxia of speech (AOS) becomes more severe and a co-occurring dysarthria often emerges. Here, longitudinal data from speakers with phonetic- and prosodic-predominant PPAOS are used to characterize the progression of their motor speech impairment, including the development of dysarthria and mutism. Method: Data are presented from 52 speakers who had PPAOS at enrollment (i.e., progressive AOS in the absence of aphasia, cognitive, or other neurologic symptoms). Twenty-one had predominantly phonetic features, whereas 31 had primarily prosodic features. All participants underwent a comprehensive motor speech evaluation at their enrollment visit and each annual return visit, with a median of three visits per participant. Results: Almost 25% of the speakers with PPAOS presented with dysarthria at their enrollment visit (median disease duration of 3.65 years), whereas more than 70% of them had developed dysarthria by their last visit (median disease duration of 6.85 years). Neither the likelihood to develop dysarthria nor the disease duration at which it was detected differed significantly between the phonetic and prosodic groups. However, muteness emerged sooner for speakers with phonetic-predominant PPAOS; the median disease duration at which they became mute was 1.5 years shorter than for their prosodic counterparts. Conclusions: Clinically, these results facilitate more accurate prognostication of motor speech symptoms in speakers with PPAOS, allowing for timely introduction of alternative means of communication. The results also support the differentiation between progressive AOS and dysarthria as distinct motor speech disorders that often co-occur in these individuals.
Microscopy assessment of a fluorescence [ 18 F] flortaucipir analog (T726) shows neuropathological overlap with 3R and 4R tau lesions
Gatto, Rodolfo G. , Hossam, Youssef, Reichard, R. Ross , Lowe, Val J. , Whitwell, Jennifer L., Josephs, Keith A. , Youssef, Hossam , Whitwell, Jennifer L , Youseff, Hossam , Whitwell, Jennifer

Mayo Clinic

Alzheimer's & Dementia | October 23, 2024 | Volume: 20 | Issue: 12 | Pages: 8758-8768

10.1002/alz.14330 | PMID 39439289 Get It

Abstract BACKGROUND [ 18 F] flortaucipir (FTP) binding to paired helical filament (PHF) tau in Alzheimer's disease (AD) is well accepted. Binding to 3R and 4R tau in frontotemporal lobar degeneration (FTLD) is controversial. We aimed to investigate whether an FTP fluorescent analog (T726) can help shed light on this controversy. METHOD We assessed T726 binding to amyloid beta (Aβ) and different tau isoforms in nine subjects (one control, three with Alzheimer's disease [AD], and five with FTLD) with different 3R and 4R tauopathies using fluorescence confocal microscopy. RESULTS T726 did not colocalize with Aβ but showed significant co‐localization with PHF tau in AD. We also observed some, albeit limited, co‐localization of T726 with 3R and 4R tau lesions in FTLD. DISCUSSION This study's findings support FTP binding to some 3R and 4R tau lesions in FTLD. Further studies are needed to understand the biology of why FTP binds some but not all FTLD tau lesions. Highlights Flortaucipir analog (T726) showed significant co‐localization with paired helical filament (PHF) tau in Alzheimer's disease (AD). Colocalization between T726 with 3R and 4R tau lesions was observed in frontotemporal lobar degeneration (FTLD). Not all 4R tau lesions bind to T726 across different FTLD brain regions.
Investigating the feasibility of 18F‐flortaucipir PET imaging in the antemortem diagnosis of primary age‐related tauopathy (PART): An observational imaging‐pathological study
Lavrova, Anna , Satoh, Ryota , Pham, Nha Trang Thu, Nguyen, Aivi T. , Jack, Clifford R. , Petersen, Ronald C. , Ross, Reichard R., Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Lavrova, Anna , Jack, Clifford R , Nguyen, Aivi T , Satoh, Ryota , Ross, Reichard R., Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2024 | Volume: 20 | Issue: 12 | Pages: 8605-8614

10.1002/alz.14301 | PMID 39417408 Get It

AbstractINTRODUCTIONPrimary age‐related tauopathy (PART) is characterized by neurofibrillary tangles and minimal β‐amyloid deposition, diagnosed postmortem. This study investigates 18F‐flortaucipir (FTP) PET imaging for antemortem PART diagnosis.METHODSWe analyzed FTP PET scans from 50 autopsy‐confirmed PART and 13 control subjects. Temporal lobe uptake was assessed both qualitatively and quantitatively. Demographic and clinicopathological characteristics and voxel‐level uptake using SPM12 were compared between FTP‐positive and FTP‐negative cases. Intra‐reader reproducibility was evaluated with Krippendorff's alpha.RESULTSMinimal/mild and moderate FTP uptake was seen in 32% of PART cases and 62% of controls, primarily in the left inferior temporal lobe. No demographic or clinicopathological differences were found between FTP‐positive and FTP‐negative cases. High intra‐reader reproducibility (α = 0.83) was noted.DISCUSSIONFTP PET imaging did not show a specific uptake pattern for PART diagnosis, indicating that in vivo PART identification using FTP PET is challenging. Similar uptake in controls suggests non‐specific uptake in PART.Highlights 18F‐flortaucipir (FTP) PET scans were analyzed for diagnosing PART antemortem. 32% of PART cases had minimal/mild FTP uptake in the left inferior temporal lobe. Similar to PART FTP uptake was found in 62% of control subjects. No specific uptake pattern was found, challenging in vivo PART diagnosis.
Editorial for “Simultaneous Increase of Mean Susceptibility and Mean Kurtosis in the Substantia Nigra as an MRI Neuroimaging Biomarker for Early‐Stage Parkinson's Disease: A Systematic Review and Meta‐Analysis”
Gatto, Rodolfo G. , Youssef, Hossam , Whitwell, Jennifer L , Youseff, Hossam

Mayo Clinic

Journal of Magnetic Resonance Imaging | September 9, 2024 | Volume: 61 | Issue: 4 | Pages: 1810-1811

10.1002/jmri.29601 | PMID 39248689 Get It

Automatic Speech Recognition in Primary Progressive Apraxia of Speech
Wiepert, Daniela A. , Botha, Hugo , Duffy, Joseph R. , Clark, Heather M. , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L. , Tetzloff, Katerina A. , Wiepert, Daniela, Botha, Hugo , Duffy, Joseph R , Clark, Heather M , Whitwell, Jennifer L , Josephs, Keith A , Utianski, Rene L , Whitwell, Jennifer L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | August 6, 2024 | Volume: 67 | Issue: 9 | Pages: 2964-2976

10.1044/2024_jslhr-24-00049 | PMID 39265154 Get It

Introduction: Transcribing disordered speech can be useful when diagnosing motor speech disorders such as primary progressive apraxia of speech (PPAOS), who have sound additions, deletions, and substitutions, or distortions and/or slow, segmented speech. Since transcribing speech can be a laborious process and requires an experienced listener, using automatic speech recognition (ASR) systems for diagnosis and treatment monitoring is appealing. This study evaluated the efficacy of a readily available ASR system (wav2vec 2.0) in transcribing speech of PPAOS patients to determine if the word error rate (WER) output by the ASR can differentiate between healthy speech and PPAOS and/or among its subtypes, whether WER correlates with AOS severity, and how the ASR's errors compare to those noted in manual transcriptions. Method: Forty-five patients with PPAOS and 22 healthy controls were recorded repeating 13 words, 3 times each, which were transcribed manually and using wav2vec 2.0. The WER and phonetic and prosodic speech errors were compared between groups, and ASR results were compared against manual transcriptions. Results: Mean overall WER was 0.88 for patients and 0.33 for controls. WER significantly correlated with AOS severity and accurately distinguished between patients and controls but not between AOS subtypes. The phonetic and prosodic errors from the ASR transcriptions were also unable to distinguish between subtypes, whereas errors calculated from human transcriptions were. There was poor agreement in the number of phonetic and prosodic errors between the ASR and human transcriptions. Conclusions: This study demonstrates that ASR can be useful in differentiating healthy from disordered speech and evaluating PPAOS severity but does not distinguish PPAOS subtypes. ASR transcriptions showed weak agreement with human transcriptions; thus, ASR may be a useful tool for the transcription of speech in PPAOS, but the research questions posed must be carefully considered within the context of its limitations. Supplemental Material: https://doi.org/10.23641/asha.26359417
Clinicopathologic and Neuroimaging Correlations of Nonverbal Oral Apraxia in Patients With Neurodegenerative Disease
García-Guáqueta, Danna P. , Botha, Hugo , Utianski, Rene L. , Duffy, Joseph R. , Clark, Heather M. , Meade, Gabriela , Machulda, Mary M. , Dickson, Dennis W. , Pham, Nha Trang Thu, Whitwell, Jennifer L. , Josephs, Keith A. , Clark, Heather M , Meade, Gabriela , Utianski, Rene L , Dickson, Dennis W , Botha, Hugo , Duffy, Joseph R , Machulda, Mary M

Mayo Clinic

Neurology | July 30, 2024 | Volume: 103 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000209717 | PMID 39079070 Get It

Incidence of Primary Progressive Apraxia of Speech and Primary Progressive Aphasia in Olmsted County, MN, 2011–2022
Turcano, Pierpaolo , Whitwell, Jennifer L. , Duffy, Joseph R. , Machulda, Mary M. , Josephs, Keith A. , Savica, Rodolfo , Mullan, Aidan, Josephs, Keith A , Savica, Rodolfo , Duffy, Joseph R , Machulda, Mary M , Mullan, Aidan F.

Mayo Clinic

Neurology | July 30, 2024 | Volume: 103 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000209693 | PMID 39079073 Get It